Department of Operative Surgery and Clinical Anatomy named after I.D. Kirpatovsky, Medical Institute Peoples' Friendship University of Russia named after Patrice Lumumba (RUDN University) Moscow Russia
Auto-generated profile, based on publicly available information
Andrei Dmitrievich Protasov
Department of Operative Surgery and Clinical Anatomy named after I.D. Kirpatovsky, Medical Institute Peoples' Friendship University of Russia named after Patrice Lumumba (RUDN University) Moscow Russia
Immunoprophylaxis is one of the most effective tools for reducing morbidity and mortality from infectious diseases. In the context of global epidemiological challenges and increased population mobility, the issues of managing immunization, proper patient selection, safety and effectiveness of vaccination are of particular importance. The document systematizes modern approaches to organizing and conducting vaccination of adults. It includes sections on planning and vaccination techniques, contraindications and "false contraindications", features of vaccination against specific infections (influenza, pneumococcal infection, hepatitis, diphtheria, tetanus, poliomyelitis, measles, rubella, etc.), as well as vaccination in pregnant women and military personnel. Particular attention is paid to the registration and treatment of post-vaccination reactions and complications, and the costeffectiveness of vaccination. The guidelines are intended for general practitioners, infectious disease specialists, epidemiologists, pediatricians, and public health specialists.
Издательство Медиа Сфера - 25 медицинских журналов общим тиражом около 500 000 экземпляров в год, представлены в международных базах данных Scopus, Medline, и Google Scolar, включены в перечень изданий ВАК, представлены в РИНЦ
Aim. To assess the long-term clinical results of vaccination with pneumococcal polysaccharide and conjugated polysaccharide vaccines in the separate and sequential use, by determining the optimal vaccination schedule in adult patients with chronic obstructive pulmonary disease (COPD) and to investigate adaptive immunity levels. Subjects and methods. The clinical effects of vaccination were evaluated in patients with COPD within 1 and 4 years after immunization against pneumococcal infection using various schemes, as well as the time course of changes in adaptive immunity indicators was examined. Results. Four years after vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13)/23-valent pneumococcal polysaccharide vaccine (PPV23) group showed a decline in the number of patients with COPD exacerbations by 50% (p
Целью исследования явилась оценка отдаленных клинических результатов вакцинации 23-валентной полисахаридной (ППВ-23) и 13-валентной конъюгированной полисахаридной (ПКВ-13) пневмококковыми вакцинами при раздельном и последовательном применении с определением оптимальной схемы вакцинации у взрослых больных бронхиальной астмой (БА). Предложена гипотетическая схема влияния противопневмококковой вакцинации на иммунопатогенез БА. Материалы и методы. Проведена оценка клинических эффектов вакцинации у больных БА в течение 1-го и 4-го годов после вакцинации против пневмококковой инфекции с использованием различных схем. Результаты. Через 1 год после вакцинации отмечалось значимое увеличение числа пациентов без обострений БА в группах ППВ-23, ППВ-23 / ПКВ-13 и ПКВ-13 / ППВ-23 (р < 0,01–0,001), а через 4 года после вакцинации – значительное увеличение числа пациентов без обострений только в группе ПКВ-13 / ППВ-23 (48,1 %; р < 0,01); при этом значимое увеличение числа пациентов без госпитализаций наблюдалось только в группе ПКВ-13 (81,8 %; р < 0,05). Предложена гипотетическая схема влияния вакцинации против пневмококковой инфекции на иммунопатогенез БА. Заключение. Пациентам с БА показано введение в комплекс базисной терапии вакцинации ПКВ-13 с последующим введением ППВ-23.
Combination vaccination against bacterial and viral infections substantially improves the major clinical parameters of COPD, positively affecting LQ indicators that generally characterize the therapeutic effect of immunization.
13 September 2019 in Epidemiology and Vaccinal Prevention
Relevance.Bronchial asthma is widespread in the world, according to WHO estimates, 235 million people suffer from it. In Russia, according to official figures, 1.3 million cases of bronchial asthma have been reported. Domestic experts reasonably believe that these data are underestimated at least 4 times. Considering that patients with bronchial asthma undergo significant changes in the immune system and are especially difficult to tolerate respiratory and other infectious diseases, determining the effect of vaccination on the clinical course of bronchial asthma is very important. The purpose of the review is to show how vaccinations against pneumococcal infection and influenza affect the condition of patients with bronchial asthma.Conclusion.Features of formation of protective immunity at various schemes of immunization against pneumococcal infection are analyzed. In patients with bronchial asthma, the justification of the vaccination scheme with the advantage of the priority administration of conjugated polysaccharide vaccine with the subsequent introduction of a polysaccharide pneumococcal vaccine after 8 weeks is given. Vaccination against pneumococcal infections has led to the elimination of sputum S. рneumoniae. In vaccination against pneumococcal infection, there was an improvement in the level of disease control, which was confirmed by the ACQ-5 test-a decrease in the indicator from 2 [1,5;1,8;3] points (lack of asthma control) to 0,6 [0;1] points (asthma control) during the year of observation, p < 0,001. Vaccination against influenza in patients with bronchial asthma leads to a decrease in the frequency and duration of exacerbations, there is a decrease in the level of markers of systemic inflammation. Combined vaccination against influenza and pneumococcal infection is not accompanied by a reliable difference in tolerability in comparison with monovaccination only against pneumococcal infection or influenza.